start portlet menu bar

Προβολή διαδικτυακού περιεχομένου

Display portlet menu
end portlet menu bar

Efficacy of a commercial vaccine containing Histophilus somni and Mannheimia haemolytica leukotoxoid (HIPRABOVIS® SOMNI/Lkt) under field conditions

Αρχική Γνώση Efficacy of a commercial vaccine containing Histophilus somni and Mannheimia haemolytica leukotoxoid (HIPRABOVIS® SOMNI/Lkt) under field conditions

Efficacy of a commercial vaccine containing Histophilus somni and Mannheimia haemolytica leukotoxoid (HIPRABOVIS® SOMNI/Lkt) under field conditions

The aim of this study was to confirm the efficacy of a commercial vaccine containing Histophilus somni and Mannheimia haemolytica leukotoxoid (HIPRABOVIS® SOMNI/Lkt) in reducing clinical respiratory signs and the number of concomitant treatments under field conditions.

Κατέβασε αυτό το άρθρο

350 KB

Σχετικά με αυτό το άρθρο

Ημερομηνία

6 Σεπ 2016

Περίληψη

Vaccination with the commercial vaccine HIPRABOVIS® SOMNI/Lkt reduced the number of animals showing clinical respiratory signs and the number of concomitant treatments used during the first three months after arrival at the fattening farm.

Σχετικές δημοσιεύσεις

Using HIPRABOVIS® SOMNI/LKT to control BRD in dairy calves: a field trial in Portugal Histophilus somni infection: an outbreak in cattle in Cental Italy Duration of immunity conferred after vaccination with HIPRABOVIS® SOMNI/LKT in young calves

Μοιραστείτε

start portlet menu bar

Vaccination against H. somni and M. haemolytica

Display portlet menu
end portlet menu bar

Δείτε επίσης

Εκδόσεις

Efficacy under field conditions of the new vaccine UBAC® in the reduction of Streptococcus...

10-07-2018
Post

Udder Health by HIPRA and CowSignals: 1 + 1 = 3

12-05-2017
Νέα

HIPRA presents UBAC®, the only specific vaccine against Strep. uberis

28-06-2018